Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DRGT 31

Next Previous
Drug Profile

DRGT 31

Alternative Names: DRGT-31; Thrombin inhibitor - Tavanta Therapeutics

Latest Information Update: 28 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Druggability Technologies
  • Developer Tavanta Therapeutics
  • Class Anticoagulants; Antithrombins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological disorders

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for preclinical development in Haematological-disorders in Hungary
  • 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
  • 15 May 2017 Preclinical trials in Haematological disorders in Hungary (Druggability Technologies pipeline, May 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top